|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that pharmacological inhibition of ABCB1 and ABCG2 during osimertinib therapy might potentially be considered to further benefit patients with brain (micro-)metastases positioned behind an intact blood-brain barrier, or with substantial expression of these transporters in the tumor cells, without invoking a high toxicity risk.
|
31175939 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that pharmacological inhibition of ABCB1 during ibrutinib therapy might benefit patients with malignancies or (micro)metastases positioned behind an intact blood-brain barrier, or with substantial expression of this transporter in the malignant cells.
|
30247919 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that pharmacological inhibition of ABCG2 and ABCB1 during ponatinib therapy might benefit patients with brain (micro)metastases positioned behind an intact blood-brain barrier, or with substantial expression of these transporters in the malignant cells.
|
28880088 |
2017 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
TPGS can inhibit P-glycoprotein, enhance drug absorption, induce mitochondrial-associated apoptosis or other apoptotic pathways, promote drug penetration and tumor accumulation, and even inhibit tumor metastasis.
|
29182031 |
2017 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Additionally, we report that MDR1 methylation correlates with regional nodal metastases in the context of two specific bacterial subpopulations, Enterobacteriaceae and Tenericutes (P < 0.001 for each).
|
22180460 |
2012 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The ABCB1 genotype CC was associated with lymph node formation (p = 0.012) and distant metastases (p = 0.019).
|
21332314 |
2011 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Specifically, P-glycoprotein and CD44 have been characterized and are known to be determinants of multidrug resistance (MDR) and metastases.
|
16061646 |
2005 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Examining ways of controlling human lung cancer metastases, we investigated the antimetastatic effect of chimeric monoclonal antibodies (MAbs) against P-glycoprotein and ganglioside GM2 (MH162 and KM966, respectively).
|
10357555 |
1999 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Since these levels were lower than expected for RCC, we asked whether the metastases possessed a phenotype different from primary RCC and examined MDR-1 expression in 5 paired cell lines derived from primary and metastatic RCC.
|
10379790 |
1999 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The identification of organ-specific cytokines that can upregulate expression of mdr-1 (or other resistant mechanisms) may suggest an approach to overcome the resistance of some metastases to particular chemotherapeutic agents.
|
10357552 |
1999 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases.
|
8898977 |
1996 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
No significant relationship was found between the expression of the resistance-related proteins P-glycoprotein or glutathione S-transferase-pi and the incidence of metastases.
|
8674274 |
1996 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, MDR1 RNA expression was less frequent in locally advanced tumors and was absent in the primary tumors of all six patients who had distant metastases.
|
8431845 |
1993 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of mdr1 gene in human breast primary tumors and metastases.
|
8251651 |
1993 |